Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11095-021-03008-w http://scihub22266oqcxt.onion/10.1007/s11095-021-03008-w 33555493!7869771!33555493     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharm+Res 2021 ; 38 (1): 3-7 Nephropedia Template TP {{tp|p=33555493|t=2021. Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics |pdf=|usr=}}{{33555493}} gab.com Text Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics JO: Pharm Res http://www.kidney.de/pget.php?&tw=1&pmid=33555493 #FOAvip Biologics are complex pharmaceuticals that include formulated proteins, plasma products, vaccines, cell and gene therapy products, and biological tissues. These products are fragile and typically require cold chain for their delivery and storage. Delivering biologics, while maintaining the cold chain, whether standard (2 degrees C to 8 degrees C) or deepfreeze (as cold as -70 degrees C), requires extensive infrastructure that is expensive to build and maintain. This poses a huge challenge to equitable healthcare delivery, especially during a global pandemic. Even when the infrastructure is in place, breaches of the cold chain are common. Such breaches may damage the product, making therapeutics and vaccines ineffective or even harmful. Rather than strengthening the cold chain through building more infrastructure and imposing more stringent guidelines, we suggest that money and effort are best spent on making the cold chain unnecessary for biologics delivery and storage. To meet this grand challenge in pharmaceutical research, we highlight areas where innovations are needed in the design, formulation and biomanufacturing of biologics, including point-of-care manufacturing and inspection. These technological innovations would rely on fundamental advances in our understanding of biomolecules and cells. Twit Text FOAVip Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics ????Pharm Res http://www.kidney.de/pget.php?&tw=1&pmid=33555493 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33555493 #FOAvip English Wikipedia <ref>{{Cite pmid|33555493}}</ref> Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics #MMPMID33555493 Yu YB; Briggs KT; Taraban MB; Brinson RG; Marino JP Pharm Res 2021[Jan]; 38 (1): 3-7 PMID33555493show ga Biologics are complex pharmaceuticals that include formulated proteins, plasma products, vaccines, cell and gene therapy products, and biological tissues. These products are fragile and typically require cold chain for their delivery and storage. Delivering biologics, while maintaining the cold chain, whether standard (2 degrees C to 8 degrees C) or deepfreeze (as cold as -70 degrees C), requires extensive infrastructure that is expensive to build and maintain. This poses a huge challenge to equitable healthcare delivery, especially during a global pandemic. Even when the infrastructure is in place, breaches of the cold chain are common. Such breaches may damage the product, making therapeutics and vaccines ineffective or even harmful. Rather than strengthening the cold chain through building more infrastructure and imposing more stringent guidelines, we suggest that money and effort are best spent on making the cold chain unnecessary for biologics delivery and storage. To meet this grand challenge in pharmaceutical research, we highlight areas where innovations are needed in the design, formulation and biomanufacturing of biologics, including point-of-care manufacturing and inspection. These technological innovations would rely on fundamental advances in our understanding of biomolecules and cells. |Biological Products/*standards/therapeutic use[MESH] |COVID-19/epidemiology/*therapy[MESH] |Humans[MESH] |Pharmaceutical Research/*standards/trends[MESH] |Refrigeration/*standards/trends[MESH]Grand Challenges in Pharmaceutical Research Series: Ridding the Cold C(epmc).pdf DeepDyve Pubget Overpricing